Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Explore strategies to prevent wasting your credit card benefits and maximize your rewards potential.
14,940 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
As the AI rally continues, XNTK’s 35-stock equal-weight tech approach is being weighed against QQQ’s Nasdaq-100 expos...
As military spending climbs worldwide, select defense stocks poised benefit due to diversified portfolios, strong cas...
Lawmakers are shifting from hearings to formal regulatory pressure, focusing on how overseas players influence crypto...
With $5,000 to invest, you don’t need a splashy portfolio. Two proven tech leaders can offer growth and staying power...
Tariff headlines keep markets guessing. This guide shows how two Vanguard index funds outperformed the S&P 500 in 202...
Markets retreat as geopolitical risk and currency headwinds weigh on miners and industrials. Linde and Southern Coppe...
A notable hedge fund takes a sizable new position in SentinelOne, signaling growing confidence in AI-driven cybersecu...
CoinFello debuts OpenClaw Skill, enabling Moltbots to perform on-chain actions through narrowly scoped delegations wh...
A careful look at tariffs shows they often translate into higher checkout prices for everyday items. This article bre...
Small-cap growth ETFs can be a powerful part of a diversified portfolio. This article compares ISCG and SLYG on costs...
Tesla’s push expand self-driving faces a new setback in the Netherlands, extending the timeline for European rollout ...